GlassScriptPhysician profile
William A Rumack
NPI 1740257542
$1,394.10
in general payments reported to CMS, 2019-2025
19 companies · $13.84 in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $283 · 2020: $108 · 2021: $716 · 2022: $116 · 2023: $98.49 · 2024: $58.19 · 2025: $13.84.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $171.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $170.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Team_makena_llc | $488.45 | 2021 | |
| Fidia Pharma USA INC. | $156.41 | 2019-2025 | Hymovis, Triluron |
| Depuy Synthes Sales INC. | $114.39 | 2019-2021 | |
| Dynasplint Systems INC. | $109.48 | 2021 | |
| Ferring Pharmaceuticals INC. | $91.00 | 2019-2020 | |
| Horizon Therapeutics Plc | $60.88 | 2019-2022 | |
| Heraeus Medical, LLC. | $49.10 | 2021-2024 | |
| Bioventus LLC | $45.09 | 2019-2022 | |
| Orthofix Medical, INC. | $35.59 | 2019 | |
| Djo, LLC | $35.22 | 2024 | Aircast |
| Saxum Surgical, INC. | $31.94 | 2023 | |
| Micromed INC | $30.14 | 2022 | |
| Davol INC. | $28.51 | 2023 | |
| Ermi LLC | $25.62 | 2019 | |
| Vericel Corporation | $21.83 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $20.48 | 2019 | |
| Biocomposites INC | $19.61 | 2020 | |
| Sanofi-Aventis U.S. LLC | $16.91 | 2023 | |
| Smith+Nephew, INC. | $13.45 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Rumack listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.